Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Summary

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.

Timeline

Start

2022-02-18

Primary completion

2033-05-28

Completion

2033-05-28

Drugs

Indications